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Abstract. MicroRNAs (miRNAs) are involved in a number 
of biological processes, including tumour biology. Pre-clinical 
studies have shown that miRNA-126 regulates signalling 
downstream of vascular endothelial growth factor receptor 2 
(VEGFR-2) and, consequently, angiogenesis. The aim of 
this study was to analyse the possible relationship between 
miRNA-126, VEGFR-2 and angiogenesis in tumour tissue 
from patients with colorectal cancer (CRC). Tumour tissue was 
obtained from 81 patients. The miRNA-126 and VEGFR-2 
gene expression levels were analysed by PCR and the protein 
concentrations of VEGFR-2 were analysed by ELISA. 
Angiogenesis, visualised by the endothelial cell marker CD105 
combined with caldesmon, was assessed by immunohisto-
chemistry and the microvessel density (MVD) technique. 
In situ hybridisation was performed for miRNA-126. Tumours 
were classified as low or high miRNA‑126‑expressing using 
the median as the cut-off. The median gene expression levels of 
VEGFR‑2 were significantly lower in the tumours expressing 
low levels of miRNA-126, 0.30 (95% CI, 0.24-0.36), compared 
to those expressing high levels of miRNA-126, 0.48 (95% CI, 
0.28-0.60), p=0.02. A positive association was observed 
with VEGFR-2 protein concentrations, p=0.06. The median 
MVD was significantly lower in the tumours expressing low 
levels of miRNA-126, 5.8 (95% CI, 5.33-6.67), compared to 
those expressing high levels, 8.0 (95% CI, 6.33-9.00), p<0.01. 
miRNA-126 was detected in endothelial cells by in situ 
hybridisation analysis. These results suggest that high levels 
of miRNA-126 in CRC are associated with high VEGFR-2 
mRNA and protein levels and a higher density of newly formed 
microvessels. However, further studies should be conducted to 
analyse the clinical value of miRNA-126 in CRC.
Introduction
Angiogenesis, the development of capillaries from pre-
existing blood vessels, is essential for the growth of malignant 
tumours (1). The vascular endothelial growth factor (VEGF) 
system plays a significant role in regulating this process (2), and 
the clinical benefit from targeting this system in patients with 
metastatic colorectal cancer (mCRC) is well documented (3).
Pre-clinical studies demonstrated a role of microRNAs 
(miRNAs) in the regulation of angiogenesis and the VEGF 
system (4,5). miRNA-126 has been reported to play an essen-
tial role in angiogenesis by modulating VEGFR-2-related 
signal transduction through the RAS/ERK and PI3K/AKT 
pathways by inhibiting regulatory units (6-9).
miRNAs are a group of small single-stranded non-coding 
RNAs with a length of approximately 22 nucleotides. They 
negatively regulate gene transcripts at a post-transcriptional 
level by targeting mRNAs leading to mRNA degradation or 
translational repression, depending on the complementarities 
between miRNA and its targets (10). It has been demonstrated 
that one miRNA may target several different mRNAs, and that 
one mRNA may be targeted by several miRNAs; several other 
principles have been suggested to explain miRNA-mediated 
gene regulation.
Approximately 1,000 unique human miRNAs have been 
identified (11). Most of the miRNAs are located in introns of 
mRNA transcripts, whereas others have been identified in 
exons, in the 3' untranslated region (3'UTR) of a gene tran-
script or in non-coding transcripts, including miRNA clusters. 
A large fraction of the identified miRNAs are located in areas 
of the genome known to be involved in the development of 
cancer and are consequently thought to play a prominent role 
in malignant transformation (10). The expression levels of 
miRNAs are often dysregulated in malignant tissue compared 
to the corresponding normal tissue, which enables miRNAs 
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to act as either tumour suppressors or oncogenes depending 
on the function of their target networks (10). An increasing 
number of reports on the clinical significance of miRNAs in 
various types of cancer, including CRC, have been published. 
Differences in expression levels between CRC and normal 
colorectal tissue have been described (12-14), and certain 
studies have also provided evidence of prognostic (15,16) and 
predictive (17) value related to miRNAs.
At present, little is known about the possible relationship 
between miRNAs and the VEGF system in patients with 
CRC. The aim of this study was to analyse the relationship 
between miRNA-126, VEGFR-2 and neo-angiogenesis in 
patients with CRC.
Materials and methods
Study population. This study included 81 consecutive patients 
with CRC during the period between February 2004 and July 
2005, all undergoing surgical resection for histologically veri-
fied adenocarcinomas of the colon or rectum at the Department 
of Surgery, Vejle Hospital, Denmark. Patients who had 
received preoperative chemoradiation for rectal cancer were 
excluded. Pre-treatment examinations included a chest X-ray 
and ultrasound or CT scan of the abdomen. Postoperatively, 
the tumours were histologically classified and staged 
according to the pTNM system. Information regarding patient 
characteristics was based on patient records and registries. 
The study was approved by the Regional Scientific Ethical 
Committee for Southern Denmark according to Danish law, 
J.nr. S-VF-20040047. Informed consent was obtained from all 
patients enrolled in the study.
Tissue sampling. Immediately after surgery the removed bowel 
segment was brought to the Department of Clinical Pathology 
and tissue from the tumour was sampled by a pathologist. 
Samples for mRNA and miRNA analyses were placed in 
RNAlater™ (Qiagen, CA, USA) and stored at ‑20˚C. Samples 
for quantitative protein analysis were frozen and stored at 
‑80˚C. The samples were frozen  within 30 min of surgical 
removal. Samples intended for later immunohistochemistry 
(IHC) and in situ hybridisation (ISH) followed routine fixa-
tion and paraffin embedding. Samples for quantitative protein 
analysis and IHC were sampled in close proximity to each 
other. Based on a microscopic examination of H&E-stained 
FFPE tumour sections, it was semi-quantitatively estimated 
that the tissue used for quantitative protein analyses was 
dominated by carcinoma cells (>50%).
VEGFR-2 mRNA and protein analyses. The VEGFR-2 
gene expression and protein analyses have previously been 
described (18). Briefly, tissue samples were homogenised and 
total RNA was isolated according to the RNeasy® mini hand-
book of June 2001 (Qiagen, MD, USA). RNA was quantified 
using spectrophotometry (Eppendorf, Hamburg, Germany) 
followed by cDNA synthesis using a M-MLV RT kit 
(Invitrogen Co., Carlsbad, CA, USA). The geometrical mean 
of β-2-microglobulin and β-actin was used for normalisation. 
Gene expression analyses were performed using fluorescence‑
based real-time reverse transcription-polymerase chain 
reaction (RT-PCR). The analyses were performed on the 
ABI PRISM 7900 HT fast real-time PCR system, TaqMan 
(Applied Biosystems, Foster City, CA, USA).
After protein extraction, VEGFR-2 was analysed 
using Quantikine ELISA kits (DVR200; R&D Systems, 
Minneapolis, MN, USA). The controls were also purchased 
from R&D Systems. The assay employs the quantitative sand-
wich enzyme immunoassay technique. Results are presented in 
pg/mg of total protein. Tissue samples, standards and controls 
were assayed in duplicate and the mean was recorded. The 
total coefficients of variation on three levels (low, medium and 
high concentrations of VEGFR-2) were 11.3, 10.1 and 8.3%, 
respectively.
CD105 and caldesmon immunostaining and MVD counting. 
The staining and counting procedures have previously been 
described (19). Briefly, MVD was measured using tissue 
sections stained by antibodies against CD105 and caldesmon 
in order to visualise immature microvessels. A kit from 
Dako (Glostrup, Denmark; code K5361, EnVision™ G⎪2 
doublestain system, rabbit/mouse, DAB+/permanent red) 
was used for the detection of primary antibodies. The anti-
CD105 antibody was obtained from Novocastra (Bristol, UK; 
endoglin NCL-CD105, clone 4G11) and used at a dilution of 
1:25. The anti-caldesmon antibody was obtained from Dako 
(code M3557, clone h-CD) and used at a dilution of 1:50.
Microvessels were counted at the invasive tumour front by 
two observers unaware of the clinical parameters. The mean 
MVD from three hotspots was used for statistical analysis. 
Any stained endothelial cell or endothelial cell cluster clearly 
separated from adjacent microvessels by tumour cells and/or 
stroma elements was considered a single countable microvessel. 
Vessel lumen was not necessary for a structure to be counted 
as a microvessel. Consensus counts resolved any discrepancy 
between the observers. Regarding the CD105 (brown) and 
caldesmon (red) staining, only microvessels without associated 
red staining were counted in order to preferentially estimate 
the MVD of the immature vessels.
miRNA-126 gene expression analyses. miRNA quantification 
was carried out using predesigned TaqMan miRNA assays 
(Applied Biosystems). cDNA synthesis, pre‑amplification 
and qPCR were performed according to the manufacturer's 
instructions. In brief, RNA was reversely transcribed using 
the TaqMan miRNA reverse transcription kit in combination 
with the stem-loop Megaplex™ primer pool A v2.0, allowing 
simultaneous reverse transcription of 377 unique miRNAs. 
Subsequently, the Megaplex RT product was pre‑amplified 
using TaqMan PreAmp master mix and Megaplex PreAmp 
primer pool A v2.0. RT‑PCR amplification of miRNA‑126 
(part no. 4395339) was performed in TaqMan Universal PCR 
master mix. Cycling conditions were as follows: 95˚C for 
10 min followed by 40 cycles of 95˚C for 15 sec and 60˚C 
for 1 min. PCR reactions were performed on the ABI PRISM 
7900 HT Fast RT-PCR system (Applied Biosystems). Raw 
Cq values were calculated using the SDS software v2.1 using 
automatic baseline and threshold settings. Expression levels 
of Hsa-miR-340 (part no. 4427975) were used for normali-
sation, since this miRNA was found by the NormFinder 
algorithm (20), a rigorous statistical approach for evaluating 
expression variation of normalisation gene candidates, to be 
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the most stably expressed transcript throughout the tissue 
samples.
miRNA-126 in situ hybridisation. ISH was performed as 
described elsewhere (21). In brief, ISH was carried out on 6-µm 
tissue sections containing CRC and normal colorectal tissue 
using double DIG-labelled LNA probes for human miRNA-
126 (Exiqon A/S, Vedbaek, Denmark). The DIG-labelled 
probe was detected with alkaline phosphatase-conjugated 
sheep anti-DIG Fab fragments followed by NBT-BCIP chro-
mogenic staining and nuclear fast red staining.
Statistical analysis. The Fisher's exact test was used for 
two-group comparisons. Median values were compared 
using the Wilcoxon rank sum test. Disease-free survival 
(DFS) was defined as the time from surgery until the first 
documented tumour recurrence or death. Progression-free 
survival (PFS) was defined as the time from surgery until the 
first documented tumour recurrence, progression or death. 
Overall survival (OS) was defined as the time from surgery 
until death. Survival curves were determined according to 
the Kaplan-Meier method, and the log-rank test was used to 
test for differences between the groups. Survival data from 
patients diagnosed with a new malignancy following their 
surgical resection for CRC (5 patients) were censored from the 
date of their new cancer diagnosis. These data were excluded 
to prevent any potential bias related to the presence of a new 
cancer or the chemotherapeutic treatments used. Statistical 
calculations were carried out using NCSS statistical software 
(NCSS Statistical Software, version 2007; Kaysville, UT, 
USA). P<0.05 was considered to be statistically significant and 
all tests were two-sided.
Results
Patient characteristics. The patient characteristics, along 
with miRNA-126 expression levels in CRC obtained by PCR 
analysis, are shown in Table I. Female patients presented 
with a significantly lower median miRNA‑126 expression 
in their tumour tissue compared to their male counterparts. 
Furthermore, non‑significant associations were observed with 
regard to age at diagnosis and tumour localisation. Younger 
patients and patients with left-sided colon cancers presented 
with a higher miRNA-126 expression. No differences were 
observed between the patient characteristics, as listed in 
Table I, and gene or protein levels of VEGFR-2 or MVD. The 
5-year survival rate for the entire cohort was 60%.
miRNA-126 expression. Paired samples of CRC and normal 
colorectal tissue were obtained from 28 patients. The 
median gene expression of miRNA-126 in CRC, 0.85 (95% 
CI, 0.71‑0.97), did not differ significantly from the median 
gene expression in normal colorectal tissue, 1.01 (95% CI, 
0.80-1.11), p=0.56. The distribution of miRNA-126 expres-
sion levels in the CRC samples for the entire patient cohort 
is shown in Fig. 1A. Tumours were classified as low or high 
miRNA-126-expressing tumours using the median as a cut-off.
The distribution of VEGFR-2 gene expression in CRC 
based on miRNA-126 levels is shown in Fig. 1B. The 
median gene expression level of VEGFR‑2 was significantly 
lower in the tumours expressing low levels of miRNA-126, 
0.30 (95% CI, 0.24-0.36), compared to those expressing high 
levels, 0.48 (95% CI, 0.28-0.60), p=0.02.
Table I. Patient characteristics.
 No. (%) miRNA-126
  --------------------------------------------------
 (n=81) Median p-value
  (95% CI)
Gender   0.04
  Male 37 (46) 1.00 (0.87-1.28)
  Female 44 (54) 0.83 (0.59-1.08)
Age (years)   0.09
  Mean (SD) 71.7 (11.1)
  Range 47-91
  >mean 44 (54) 0.85 (0.89-1.48)
  <mean 37 (46) 1.02 (0.89-1.48)
T category   0.72
  1-3 63 (78) 0.97 (0.82-1.12)
  4 18 (22) 0.79 (0.59-1.48)
N category   0.81
  0 46 (57) 0.99 (0.72-1.13)
  1-2 35 (43) 0.96 (0.77-1.28)
M category   0.57
  0 65 (80) 0.96 (0.81-1.12)
  1 16 (20) 0.90 (0.70-1.69)
Stage   0.73
  I-II 43 (53) 1.01 (0.68-1.13)
  III-IV 38 (47) 0.95 (0.77-1.28)
Localisation
  Rectum 20 (25) 0.88 (0.70-1.48) 0.88
  Colon 61 (75) 0.98 (0.77-1.23) 0.07
    Left colon 28 (46) 1.05 (0.94-1.47)
    Right colon 33 (54) 0.77 (0.56-1.13)
MSI status   0.33
  MSI 15 (19) 0.72 (0.38-1.24)
  MSS 66 (81) 0.96 (0.82-1.08)
Tumour grade   0.74
  1 and 2 61 (75) 0.95 (0.79-1.08)
  3  20 (25) 0.96 (0.59-1.58)
Vascular invasion   0.42
  Yes 10 (12) 1.08 (0.70-1.73)
  No 71 (88) 0.96 (0.79-1.02)
Neuronal invasion   0.18
  Yes 10 (12) 1.32 (0.70-1.87)
  No 71 (88) 0.94 (0.77-1.02)
Peritoneal   0.33
perforation
  Yes 17 (21) 0.77 (0.59-1.36)
  No 64 (79) 0.97 (0.83-1.12)
CI, confidence interval; SD, standard deviation; MSI, microsatellite 
instable; MSS, microsatellite stable.
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The distribution of VEGFR-2 protein concentrations in 
CRC based on miRNA-126 levels is shown in Fig. 1C. The 
median protein concentration of VEGFR-2 was slightly lower, 
although not significant, in the tumours expressing low levels of 
miRNA-126, 115 pg/mg (95% CI, 98-140), compared to those 
expressing high levels, 134 pg/mg (95% CI, 121-180), p=0.06.
The median MVD was significantly lower in the tumours 
expressing low levels of miRNA-126, 5.8 (95% CI, 5.33-
6.67), compared to those expressing high levels, 8.0 (95% CI, 
6.33-9.00), p<0.01 (Fig. 1D). 
miRNA-126 in situ hybridisation. ISH analyses using high- 
affinity LNA probes revealed intense ISH signals in endothe-
lial cells. miRNA-126-positive vessels were observed in the 
tumour stroma, as well as in the lamina propria of normal 
mucosa and in the deep unaffected bowel wall (Fig. 2).
miRNA-126 and prognosis. The possible prognostic value of 
miRNA-126 expression in CRC was assessed by comparing 
patients with a low expression of miRNA-126 to those with a 
high expression, using the median as the cut-off. Neither PFS 
[hazard ratio 0.85 (95% CI, 0.44-1.64)] nor OS [hazard ratio 
0.99 (95% CI, 0.49‑1.98)] differed significantly between the 
two groups (p=0.64 and p=0.98, respectively).
Our patient cohort included a total of 28 patients with micro-
satellite stable (MSS) stage II CRC and, within this subgroup, 
short DFS was significantly linked to high miRNA‑126 expres-
sion levels (Fig. 3).
Discussion
In the present pilot study, a direct correlation was found 
between miRNA-126, VEGFR-2 and angiogenesis in samples 
from patients with CRC.
Paired samples of CRC and normal colorectal tissue 
were obtained from 28 patients, and the median miRNA-126 
expression level in the two tissue types did not differ signifi-
cantly. Guo et al (7) demonstrated that the miRNA-126 level 
was significantly lower in colon cancer compared to normal 
colon tissue in a panel of 6 paired samples. In both cases, the 
results are based on a rather limited number of paired samples 
and should therefore be interpreted with caution. Furthermore, 
the use of different normalisation methods (Guo et al used 
5S rRNA) may also be significant in this context.
The miRNA‑126 expression in CRC was significantly 
lower in females compared to males, and a possible, albeit 
non‑significant, difference was also observed regarding age 
and tumour localisation. The miRNA-126 expression tended 
to be lower in the older group of patients and in patients with 
right-sided colon cancers.
Based on these findings, a correlation with microsatellite 
instable (MSI) status was expected. However, no such correla-
tion was found in the present study. Díaz et al (15) analysed 
several miRNAs in 110 patients who underwent surgery for 
CRC. miRNA-126 expression was found to be significantly 
lower in the youngest group of patients and no significant 
association with gender was documented. These discrepancies 
  A   B
  C   D
Figure 1. (A) Distribution of miRNA-126 gene expression in CRC tissue. (B) Distribution of VEGFR-2 gene expression in CRC tissue according to miRNA-126 
levels, p=0.02. (C) Distribution of VEGFR-2 protein concentration in CRC tissue according to miRNA-126 levels, p=0.06. (D) Distribution of CD105-positive 
microvessel density in CRC tissue according to miRNA-126 levels, p<0.01. Black bars, medians, n=81.
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are difficult to explain since the two studies involved a 
similar number of patients, included Caucasians only, used 
almost the same methodology, although Díaz et al used 5S 
for normalisation, and also included patients with stage I-IV 
disease. The study by Díaz et al used fresh-frozen tumour 
tissue compared to the present study in which miRNA was 
extracted from tissue preserved in RNAlater. A possible effect 
on miRNA-126 expression levels by directly comparing pres-
ervation in RNAlater and freezing of the tissue specimens 
remains to be clarified.
A high miRNA-126 expression was correlated to a high 
gene expression of VEGFR-2 and likely also to high protein 
concentrations of VEGFR-2 in CRC, although the latter 
correlation did not reach statistical significance (p=0.06). 
Furthermore, a high miRNA‑126 expression was significantly 
correlated to a higher density of newly formed micro 
vessels. These results, obtained in a clinical setting, suggest 
a relationship between the VEGF system, neo-angiogenesis 
and miRNA-126, and correlate well with results reported 
in the pre-clinical literature. Two recent studies (6,9) have 
demonstrated the significant role of miRNA‑126 in media‑
ting developmental angiogenesis and identified two specific 
targets for miRNA-126, i.e., the sprouty-related, EVH1 
domain-containing protein 1 (SPRED-1) and the phospho-
inositol-3 kinase regulatory subunit 2 (PIK3R2), both acting 
as negative regulators of the RAS/ERK and PI3K/AKT 
pathways, respectively. miRNA-126 is capable of potenti-
ating the angiogenic signalling downstream of VEGFR-2 by 
modulating the signals through these pathways. Other studies 
have demonstrated a similar regulatory role of miRNA-126 
with regard to these pathways (7,22). In 2010, Nicoli et al 
(8) published results suggesting that blood flow stimulates 
angiogenesis in the zebrafish by a genetic pathway in which 
a transcription factor (klf2a) induces the expression of 
miRNA-126 and thereby enhances VEGF-A signalling. These 
pre‑clinical studies, confirm that high levels of miRNA‑126 
increase signalling downstream of VEGFR-2, ultimately 
resulting in increased angiogenesis. To a certain extent, this 
increase is supported by the present results obtained in a 
clinical setting.
Our results showed a relationship between miRNA-126, 
VEGFR-2 and neo-angiogenesis estimated by CD105 MVD, 
suggesting that miRNA-126 expression was correlated to 
tissue vascularisation. The miRNA-126 ISH analyses revealed 
an expression in endothelial cells in malignant and normal 
colorectal tissue similar to results from various in vitro 
studies (5,6,8,9). These observations indicate high and specific 
miRNA-126 expression levels in endothelial cells. The clinical 
value of the miRNA-126 ISH analyses, which may be an alter-
native to the MVD technique based on IHC, deserves further 
analysis using larger patient cohorts.
The possible prognostic value of miRNA-126 expression 
in CRC was analysed. However, no significant correlation 
with survival was found in the unselected patient cohort, 
which corresponds to the results obtained by Díaz et al (15). A 
subgroup analysis consisting of patients with stage II disease 
only and MSS tumours is relevant due to the need to identify 
new prognostic markers in stage II CRC, and the well-known 
prognostic difference between MSI and MSS tumours (23) 
justifies this selection. Although this subgroup only consisted 
of 28 patients in the present study, it is significant that 
Figure 2. miRNA-126 ISH. (A and B) Expression of miRNA-126 in normal 
colon tissue. (C) Expression in colon cancer tissue. The miRNA-126 
ISH signal is observed in endothelial cells and is not confined to tumour‑ 
associated vessels.
  A
  B
  C
Figure 3. Kaplan-Meier DFS curves according to miRNA-126 expression in 
patients with stage II and MSS tumours, n=28 (14 patients in each group). 
The solid line pertains to patients with a low miRNA-126 expression and the 
dashed line to patients with a high miRNA-126 expression, p=0.03.
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our observations are consistent with the findings reported 
by Schepeler et al (16). These authors demonstrated that 
miRNA-126, among other miRNAs, was up-regulated 
in the primary tumour tissue from patients with stage II 
MSS colon cancers who experienced relapse significantly 
later compared to those that did not. A meaningful multi-
variate survival analysis was not conducted due to the small 
sample size. Therefore, although miRNA-126 expression 
in CRC does not appear to be of prognostic value in the 
entire patient cohort, it may harbour a prognostic impact 
for a selected group of CRC patients. The meta-analysis by 
Des et al demonstrated a correlation between high MVD 
and poor prognosis in CRC (24). The present relationship 
between high MVD and high miRNA-126 expression in the 
present study provides a plausible explanation for these find-
ings, although this hypothesis requires validation in a larger 
patient cohort.
In conclusion, significant associations were found between 
miRNA-126 levels in CRC, VEGFR-2 gene expression and 
neo-angiogenesis, although a great overlap was observed 
between the compared groups. Conclusions should therefore 
be drawn with caution, and additional testing in larger and 
more homogeneous study populations is necessary to validate 
the results. The present results correspond well with the pre-
clinical literature, indicating a pivotal role of miRNA-126 in 
the modulation of angiogenesis (6-9,25). Thus, miRNA-126 
may harbour predictive information with regard to anti- 
angiogenetic therapy. A better understanding of how this 
miRNA is regulated is of great significance. Further studies 
that analyse the clinical value of miRNA-126 in CRC, are 
therefore required.
Acknowledgements
The authors are grateful for the technical assistance provided 
by Lone Frischknecht, Lone Hartmann Hansen, Sara Egsgaard, 
Birgit Roed Sørensen, Pamela Celis and Karin Larsen. This 
study was supported by The Cancer Foundation, which had no 
influence on any part of the study.
References
  1. Folkman J: What is the evidence that tumors are angiogenesis 
dependent? J Natl Cancer Inst 82: 4-6, 1990.
  2. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and 
its receptors. Nat Med 9: 669-676, 2003.
  3. Wagner AD, Arnold D, Grothey AA, Haerting J and 
Unverzagt S: Anti-angiogenic therapies for metastatic colorectal 
cancer. Cochrane Database Syst Rev 8: CD005392, 2009.
  4. Hua Z, Lv Q, Ye W, et al: MiRNA-directed regulation of VEGF 
and other angiogenic factors under hypoxia. Plos One 1: E116, 
2006.
  5. Kuehbacher A, Urbich C, Zeiher AM and Dimmeler S: Role 
of Dicer and Drosha for endothelial microRNA expression and 
angiogenesis. Circ Res 101: 59-68, 2007.
  6. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, 
Ivey KN, Bruneau BG, Stainier DY and Srivastava D: miR-126 
regulates angiogenic signaling and vascular integrity. Dev 
Cell 15: 272-284, 2008.
  7. Guo C, Sah JF, Beard L, Willson JK, Markowitz SD and 
Guda K: The noncoding RNA, miR-126, suppresses the growth 
of neoplastic cells by targeting phosphatidylinositol 3-kinase 
signaling and is frequently lost in colon cancers. Genes 
Chromosomes Cancer 47: 939-946, 2008. 
  8. Nicoli S, Standley C, Walker P, Hurlstone A, Fogarty KE and 
Lawson ND: MicroRNA-mediated integration of haemody-
namics and Vegf signalling during angiogenesis. Nature 464: 
1196-1200, 2010.
  9. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, 
Richardson JA, Bassel-Duby R and Olson EN: The endothe-
lial‑specific microRNA miR‑126 governs vascular integrity and 
angiogenesis. Dev Cell 15: 261-271, 2008.
10. Esquela-Kerscher A and Slack FJ: Oncomirs – microRNAs with 
a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
11. Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms 
of post-transcriptional regulation by microRNAs: are the 
answers in sight? Nat Rev Genet 9: 102-114, 2008.
12. Faber C, Kirchner T and Hlubek F: The impact of microRNAs 
on colorectal cancer. Virchows Arch 454: 359-367, 2009.
13. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP 
and James RJ: Reduced accumulation of specific microRNAs in 
colorectal neoplasia. Mol Cancer Res 1: 882-891, 2003.
14. Yamamichi N, Shimomura R, Inada K, et al: Locked nucleic 
acid in situ hybridization analysis of miR-21 expression during 
colorectal cancer development. Clin Cancer Res 15: 4009-4016, 
2009.
15. Díaz R, Silva J, Garcia JM, Lorenzo Y, Garcia V, Pena C, 
Rodriguez R, Munoz C, Garcia F, Bonilla F and Dominguez G: 
Deregulated expression of miR-106a predicts survival in human 
colon cancer patients. Genes Chromosomes Cancer 47: 794-802, 
2008.
16. Schepeler T, Reinert JT, Ostenfeld MS, et al: Diagnostic and 
prognostic microRNAs in stage II colon cancer. Cancer Res 68: 
6416-6424, 2008.
17. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, 
Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, 
Calin GA, Croce CM and Harris CC: MicroRNA expression 
profiles associated with prognosis and therapeutic outcome in 
colon adenocarcinoma. Jama 299: 425-436, 2008.
18. Hansen TF, Spindler KL, Lorentzen KA, Olsen DA, 
Andersen RF, Lindebjerg J, Brandslund I and Jakobsen A: 
Quantitative analysis of vascular endothelial growth factor 
receptors 1 and 2 in colorectal cancer. Mol Med Reports 2: 
787-792, 2009.
19. Hansen TF, Sorensen FB, Spindler KL, Olsen DA, Andersen RF, 
Lindebjerg J, Brandslund I and Jakobsen A: Microvessel density 
and the association with single nucleotide polymorphisms of the 
vascular endothelial growth factor receptor 2 in patients with 
colorectal cancer. Virchows Arch 456: 251-260, 2010.
20. Andersen CL, Jensen JL and Orntoft TF: Normalization 
of real-time quantitative reverse transcription-PCR data: a 
model-based variance estimation approach to identify genes 
suited for normalization, applied to bladder and colon cancer 
data sets. Cancer Res 64: 5245-5250, 2004.
21. Jorgensen S, Baker A, Moller S and Nielsen BS: Robust one-day 
in situ hybridization protocol for detection of microRNAs in 
paraffin samples using LNA probes. Methods 52: 375‑381, 2010.
22. Kuhnert F, Mancuso MR, Hampton J, Stankunas K, Asano T, 
Chen CZ and Kuo CJ: Attribution of vascular phenotypes of the 
murine Egfl7 locus to the microRNA miR‑126. Development 135: 
3989-3993, 2008.
23. Ionov Y, Peinado MA, Malkhosyan S, Shibata D and Perucho M: 
Ubiquitous somatic mutations in simple repeated sequences 
reveal a new mechanism for colonic carcinogenesis. Nature 363: 
558-561, 1993.
24. Des GG, Uzzan B, Nicolas P, Cucherat M, Morere JF, 
Benamouzig R, Breau JL and Perret GY: Microvessel density 
and VEGF expression are prognostic factors in colorectal cancer. 
Meta-analysis of the literature. Br J Cancer 94: 1823-1832, 2006.
25. Kuehbacher A, Urbich C and Dimmeler S: Targeting microRNA 
expression to regulate angiogenesis. Trends Pharmacol Sci 29: 
12-15, 2008.
